Company intelligence / Profile preview
Sferogen
Ajdovščina or Ljubljana, Sloveniasferogen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sferogen has demonstrated strong preclinical immunogenicity with its nanoSFERIC-based vaccine candidates. Its eVLP COVID vaccine showed immune responses in mice on par with approved vaccines. The company is advancing a Nipah virus vaccine for pandemic preparedness and has developed scalable clinical-grade manufacturing processes.
- Therapeutic areas
- ImmunologyOncologyInfectious DiseasesOther
- Modalities
- Recombinant proteinNanoparticleEnveloped virus-like particle (eVLP)Protein nanoparticleVaccine (as a product class)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Not specified; open to partnerships
Beyond the preview
Go deeper on Sferogen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sferogen.